Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

May 14, 2019May 14, 2019

Cognitive Function May Be Affected in Adults with Sickle Cell Disease, Study Suggests

News

Adults with sickle cell disease score worse than their healthy, unaffected siblings on cognitive tests, despite treatment with hydroxyurea, a study reports. The study “Neurocognitive functioning in symptomatic adults ... Read more

March 21, 2019March 21, 2019

More Curative Bone Marrow Transplants are Successful When Patients Given Double the Radiation Beforehand, Study Says

News

The success rate of bone marrow transplants for patients with sickle cell disease or beta thalassemia, from only “half-matched” donors, increased by doubling the radiation delivered to patients’ bodies ... Read more

February 28, 2019February 28, 2019

First Patient Enrolled in Phase 1/2 Trial Testing CTX001 for Severe Sickle Cell Disease

News

A Phase 1/2 clinical trial evaluating investigational therapy CTX001 for severe sickle cell disease (SCD) has enrolled its first patient in the U.S., and treatment is expected to begin by mid-2019. The ... Read more

January 22, 2019January 22, 2019

Safety and Early Hints of Benefit Seen in Phase 1b Trial of PF-04447943

News

Sickle cell disease (SCD) patients were safely treated with a phosphodiesterase 9A (PDE9) inhibitor therapy called PF-04447943 with no serious side effects reported and possible evidence of fewer vaso-occlusion ... Read more

January 7, 2019January 8, 2019

CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell Disease

News

The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease. A Phase 1/2 clinical trial (NCT03745287) is recruiting patients. CTX001 uses the CRISPR gene-editing technology ... Read more

April 19, 2018April 19, 2018

Sickle Cell Disease Researchers Identify a Children’s Stroke Prediction Tool

News

The amount of oxygen the blood loses when traveling through the brain could help identify children with sickle cell disease who are at risk of having a stroke, a ... Read more

March 27, 2018March 27, 2018

Sickle Cell Patients at Higher Risk for ER Readmission, Hospitalization, Study Finds

News

Patients with sickle cell disease show the highest rates of readmission and hospitalization within 30 days of being discharged from an emergency department, a single-center study found. The study, ... Read more

February 15, 2018February 15, 2018

Imara Begins Phase 2 Sickle Cell Disease Trial Testing IMR-687 in Adults

News

Imara, a pharmaceutical company developing new therapies for sickle cell disease (SCD), has successfully dosed the first patient enrolled in its clinical trial evaluating escalating doses of IMR-687 in ... Read more

February 8, 2018February 8, 2018

Hypersensitivity to Allergens May Increase Risk of Acute Chest Syndrome in Sickle Cell Anemia Children

News

Hypersensitivity to allergens in children with sickle cell anemia may increase the risk of acute chest syndrome, a study suggests. The study “Aeroallergen sensitization predicts acute chest syndrome in children ... Read more

January 9, 2018January 9, 2018

Bluebird Bio Presents Positive Early Results of Gene Therapy LentiGlobin for Sickle Cell Disease

News

Bluebird bio announced encouraging interim results from the ongoing Phase 1 clinical trial testing its investigational gene therapy LentiGlobin for patients with severe sickle cell disease (SCD). The results were ... Read more